

> Transplantation of donor pluripotent cells that can reconstitute all recipient blood lineages


# HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

_Transplantation of donor pluripotent cells that can reconstitute all recipient blood lineages_

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Categories of Stem Cell Transplantation</b></p></td></tr><tr><td><p><b>Feature</b></p></td><td><p><b>Allogeneic (Allo)</b></p></td><td><p><b>Autologous (Auto)</b></p></td></tr><tr><td><p>Donor-recipient relationship</p></td><td><p>Immunologically distinct</p></td><td><p>Donor is also recipient</p></td></tr><tr><td><p><b><i>Graft-vs.-host disease</i></b></p></td><td><p><b><i>Yes</i></b></p></td><td><p><b><i>No</i></b></p></td></tr><tr><td><p><b><i>Graft-vs.-tumor effect</i></b></p></td><td><p><b><i>Yes</i></b></p></td><td><p><b><i>No</i></b></p></td></tr><tr><td><p>Risk of graft contam. with tumor</p></td><td><p>No</p></td><td><p>Yes</p></td></tr><tr><td><p>Relapse risk (leukemia)</p></td><td><p>Lower</p></td><td><p>Higher</p></td></tr><tr><td><p><b><i>Transplant-related mortality</i></b></p></td><td><p><b><i>Higher</i></b></p></td><td><p><b><i>Lower</i></b></p></td></tr></tbody></table>

• **Types of Allo HSCT:** _based on donor/recipient matching of major HLA antigens on Chr. 6_ (4 principal genes for serotyping: _HLA-A_, _\-B_, -_C_, & _\-DR;_ each with 2 alleles ∴ 8 major Ag)

_Matched related_ (MRD, sibling 8/8 major Ag match): lowest GVHD; **preferred donor**

_Matched unrelated (MUD):_ ↑ risk of GVHD; ∴ matching of 10 HLA alleles (_DQ_ also) to ↓ risk; chance of match correlates with ethnicity (_NEJM_ 2014;371:339)

_Mismatched related_ (eg, 1/8 Ag mismatch): ↑ available donor pool, but ↑ GVHD, rejection; ∴ need additional immunosuppression

_Haploidentical_: typically, between parents and children (“half” match); early post-tx cyclophosphamide reduces GVH by destroying proliferating alloreactive T-cells

_Umbilical cord blood:_ HSC processed at birth & stored. Low cell number, need 2 cords in adults. Neonatal immune cells: HLA-mismatch tolerated better, ↓ GVHD, slow immune reconstitution → ↑ late viral infections (_Blood_ 2010;116:4693)

• **Graft-vs.-host disease (GVHD):** _undesirable_ side effect of allo HSCT allogeneic T cells view host cells as foreign; ↑ incid. with mismatch or unrelated donors

• **Graft-vs.-tumor (GVT):** _desired_ effect in allo-SCT; graft T cells attack host tumor cells

Indications (_BBMT_ 2015;21:1863; _BMT_ 2015;50:1037)

• **Malignant disease:**

### Auto HSCT allows _high-dose myeloablative chemo_ and then rescue what would be otherwise lethal cytopenias with autologous stem cells. Used in chemosensitive diseases such as relapsed/refractory DLBCL, MM, testicular germ cell tumor.

### Allo HSCT produces **graft-vs.-tumor** (GVT) effect, in addition to hematopoietic rescue (used for AML, ALL, MDS, CML-blast crisis, CLL, lymphoma)

• **Nonmalignant disease:** allo HSCT replaces 異常 lymphohematopoietic system with one from 正常 donor (eg, immunodeficiencies, aplastic anemia, hemoglobinopathies)

Transplantation procedure (for Allo HSCT)

• **Pre-tx preparative regimen goal:** immunosuppression to allow donor cell engraftment & anti-tumor efficacy to ↓ relapse risk. Type and dose of agents determine this balance.

_Myeloablative conditioning_: high-dose chemo and/or total body irradiation. Low relapse rates, high immunosuppression, high transplant–related morbidity.

_Reduced-intensity conditioning (“RIC”)_: lower dose of chemo → ↓ transplant-related morbidity/mortality, but ↑ relapse b/c it relies more on GVT effect (_Blood_ 2015;126:23). Allows allo HSCT for older adults (>60) or 病人 with comorbidities.

• **Sources of stem cells** (_NEJM_ 2012;367:1487)

**Bone marrow (BM):** original source of HSCT, now less commonly used than PBSC

**Peripheral blood stem cells (PBSC):** easier to collect, more commonly used. BM vs. PBSC ≈ survival; BM ↓ chronic GVHD, PBSC ↓ graft failure, faster engraftment.

**Umbilical cord blood stem cells (UCB):** see above in Types of Allo HSCT

• **Engraftment:** absolute neutrophil count (ANC) recovers to 500/µL within ~2 wk with PBSC, ~2.5 wk with BM, ~4 wk with UCB. G-CSF accelerates recovery by 3–5 d in all scenarios.

_Engraftment syndrome:_ fever, rash, noncardiogenic pulm edema, 異常 LFTs, AKI, wt gain. Dx of exclusion: 排除 infection, GVHD; Rx with 1 mg/kg steroids, rapid taper over 3–4 d.

Complications

• Either **direct chemoradiotoxicities** associated with preparative regimen or consequences of **interaction between donor and recipient immune systems**

• **Sinusoidal obstruction syndrome (SOS):** incidence ~10%, mortality ~30%

Previously known as **veno-occlusive disease (VOD)** (_BBMT_ 2016;22:400). Mechanism: direct cytotoxic injury to hepatic venules → _in situ_ thrombosis.

Symptoms: tender hepatomegaly, ascites, jaundice, fluid retention with severe disease → liver failure, encephalopathy, hepatorenal syndrome

Diagnosis: ↑ ALT/AST, ↑ bilirubin; ↑ PT with severe disease; Doppler U/S _may_ show reversal of portal vein flow; ↑ hepatic wedge pressure; 異常 liver bx

治療: supportive; prophylaxis with **ursodiol;** treat with defibrotide (_Blood_ 2016;127:1656)

• **Idiopathic pneumonia syndrome (IPS):** 5–25% of 病人, >50% mortality (_Blood_ 2003;102:2777)

Alveolar injury 2/2 direct toxicity → fever, hypoxia, diffuse infiltrates; occult infxn frequent

• **Diffuse alveolar hemorrhage (DAH):** Diagnosis: bronchoscopy to exclude infection; ↑ bloody lavage fluid seen with DAH. 治療: pulse 500–1000 mg Solu-Medrol × 3 d ± etanercept (_BBMT_ 2015;1:67).

• **Acute GVHD** (usually within 6 mo of transplant; _NEJM_ 2017;377:2167)

臨床grades I–IV based on scores for **skin** (severity of maculopapular rash), **liver** (bilirubin level) and **GI** (volume of diarrhea); bx supports diagnosis

Prevention: **immunosuppression** (MTX + CsA or tacrolimus) or T-cell depletion of graft

治療: grade I → topical Rx; grades II–IV → associated with ↓ survival and ∴ treated with immunosuppressants (corticosteroids, CsA, tacrolimus, rapamycin, MMF)

• **Chronic GVHD** (developing or persisting >3 mo posttransplant; _NEJM_ 2017;377:2565)

Clinical: malar rash, sicca syndrome, arthritis, obliterative bronchiolitis, bile duct degeneration, cholestasis and many others. More common with PBSC than BM.

治療: immunosuppression; rituximab; photopheresis; ibrutinib (_Blood_ 2017;130:21)

• **Graft failure**

Primary = persistent neutropenia withoutut evidence of engraftment

Secondary = delayed pancytopenia after initial engraftment; either immune mediated via immunocompetent host cells (**graft rejection**) or non–immune mediated (eg, CMV)

• **Infectious complications**

due to regimen-induced pancytopenia and immunosuppression

auto HSCT recipients: no immunosuppression ∴ at ↑ risk only pre-/postengraftment

both primary infections and reactivation events occur (eg, CMV, HSV, VZV)

![](https://i.imgur.com/PgthhWx.jpg)

\*Primarily among persons who are seropositive before transplant.

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Prophylaxis/Supportive Medications During HSCT</b></p></td></tr><tr><td><p><b>Medication</b></p></td><td><p><b>Prophylaxis Against</b></p></td><td><p><b>Duration</b></p></td></tr><tr><td><p>Fluconazole or posaconazole</p></td><td><p><i>Candida</i></p></td><td><p>75 d</p></td></tr><tr><td><p>Acyclovir</p></td><td><p>HSV/VZV</p></td><td><p>365 d</p></td></tr><tr><td><p>Valganciclovir or ganciclovir if CMV ⊕</p></td><td><p>CMV</p></td><td><p>100 d or when no longer immunosuppressed</p></td></tr><tr><td><p>Antibiotics (eg, fluoroquinolone)</p></td><td><p>Bacterial infxn</p></td><td><p>While neutropenic</p></td></tr><tr><td><p>TMP-SMX</p></td><td><p>PCP</p></td><td><p>365 d or when off immunosupp.</p></td></tr><tr><td><p>Allopurinol</p></td><td><p>Hyperuricemia</p></td><td><p>Until d –1</p></td></tr><tr><td><p>Ursodiol</p></td><td><p>SOS/VOD</p></td><td><p>60 d</p></td></tr></tbody></table>
